Month: April 2025

Categories : Diet and NutritionTags :

Cinnamon Could Affect Drug Metabolism in the Body

On By ModernMedia
Photo by Rens D on Unsplash

Cinnamon is one of the oldest and most commonly used spices in the world – but a new study from the University of Mississippi indicates a compound in it could interfere with some prescription medications.

In a recent study published in Food Chemistry: Molecular Sciences, the researchers found that cinnamaldehyde, a primary component of cinnamon, activates receptors that control the metabolic clearance of medication from the body, meaning consuming large amounts of cinnamon could reduce the effects of drugs.

“Health concerns could arise if excessive amounts of supplements are consumed without the knowledge of health care provider or prescriber of the medications,” said Shabana Khan, a principal scientist in the natural products centre. “Overconsumption of supplements could lead to a rapid clearance of the prescription medicine from the body, and that could result in making the medicine less effective.”

Aside from its culinary uses, cinnamon has a long history of being used in traditional medicine and can help manage blood sugar and heart health and reduce inflammation. But how the product actually functions in the body remains unclear.

Sprinkling cinnamon on your morning coffee is unlikely to cause an issue, but using highly concentrated cinnamon as a dietary supplement might.

“Despite its vast uses, very few reports were available to describe the fate of its major component – cinnamaldehyde,” Khan said. “Understanding its bioaccessibility, metabolism and interaction with xenobiotic receptors was important to evaluate how excess intake of cinnamon would affect the prescription drugs if taken at the same time.”

Not all cinnamon is equal. Cinnamon oil – which is commonly used topically as an antifungal or antibacterial and as a flavouring agent in food and drinks – presents almost no risk of herb-drug interactions, said Amar Chittiboyina, the center’s associate director.

But cinnamon bark – especially Cassia cinnamon, a cheaper variety of cinnamon that originates in southern China – contains high levels of coumarin, a blood thinner, compared to other cinnamon varieties. Ground Cassia cinnamon bark is what is normally found in grocery stores.

“In contrast, true cinnamon from Sri Lanka carries a lower risk due to its reduced coumarin content,” he said. “Coumarin’s anticoagulant properties can be hazardous for individuals on blood thinners.”

More research is needed to fully understand the role that cinnamon plays in the body and what potential herb-drug interactions may occur, said Bill Gurley, a principal scientist in the Ole Miss center and co-author of the study.

“We know there’s a potential for cinnamaldehyde to activate these receptors that can pose a risk for drug interactions,” he said. “That’s what could happen, but we won’t know exactly what will happen until we do a clinical study.”

Until those studies are complete, the researchers recommend anyone interested in using cinnamon as a dietary supplement to check with their doctor first.

“People who suffer from chronic diseases – like hypertension, diabetes, cancer, arthritis, asthma, obesity, HIV, AIDS or depression – should be cautious when using cinnamon or any other supplements,” Khan said. “Our best advice is to talk to a health care provider before using any supplements along with the prescription medicine.

“By definition, supplements are not meant to treat, cure or mitigate any disease.”

Source: University of Mississippi

Categories : General Interest Injury & TraumaTags :

Roman-era Skeleton from Britain is Rare Evidence of Human–animal Gladiator Combat

On By ModernMedia

The bones show evidence of bite marks from a large cat such as a lion, used in some gladiator shows

Although most Roman-era gladiators are believed to have mostly fought animal as well as human opponents, to date there has been little archaelogical evidence of this. Photo by David Cruz asenjo

A skeleton from Roman-era England has bite marks consistent with those of a large cat like a lion, suggesting that this individual may have died as part of a gladiator show or execution, according to a study published April 23, 2025 in the open-access journal PLOS One by Tim Thompson from Maynooth University, Ireland, and colleagues.

Records of gladiator combat in the Roman Empire have been well-documented, with evidence of both human-human conflicts and fights between humans and animals such as lions and bears. But actual gladiator remains are relatively scarce in the archaeological record – and in Britain specifically, which was occupied by the Romans from the first through fifth centuries, there has so far been no confirmed evidence of human-animal combat.

Puncture injuries by large felid scavenging on both sides of bone. Credit: Thompson et al., 2025, PLOS One, CC-BY 4.0

The skeleton described in the new paper was likely buried sometime between 200-300 CE, near the Roman city of Eboracum, which is now York. This site contains the remains of mostly younger men, often with evidence of trauma, which has led to speculation that it could be a gladiator burial site. This specific skeleton has a series of depressions on the pelvis, which had previously been suggested as possible evidence of carnivore bites. By creating a three-dimensional scan of these marks, the researchers on this new study could compare these marks to bites from a variety of different animals.

They determined that these marks were likely bite marks from a large cat, possibly a lion. Since they were on the pelvis, they note it’s possible that these bites came as a result of the lion scavenging on the body around the time of death.

This skeleton is the first direct, physical evidence of human-animal combat from Europe during the Roman Empire. By demonstrating the possibility of gladiatorial combat or similar spectacles in modern York, this finding also gives archaeologists and historians new insight into the life and history of Roman-era England.

Lead author Prof Tim Thompson, of Maynooth University, adds: “The implications of our multidisciplinary study are huge. Here we have physical evidence for the spectacle of the Roman Empire and the dangerous gladiatorial combat on show. This provides new evidence to support our understanding of the past.”

Co-author Dr John Pearce, of King’s College London, adds: “As tangible witnesses to spectacles in Britain’s Roman amphitheatres, the bitemarks help us appreciate these spaces as settings for brutal demonstrations of power. They make an important contribution to desanitising our Roman past.”   

David Jennings, CEO of York Archaeology, adds: “One of the wonderful things about archaeology is that we continue to make discoveries even years after a dig has concluded, as research methods and technology enable us to explore the past in more detail; it is now 20 years since we unearthed 80 burials at Driffield Terrace. This latest research gives us a remarkable insight into the life – and death – of this particular individual, and adds to both previous and ongoing genome research into the origins of some of the men buried in this particular Roman cemetery. We may never know what brought this man to the arena where we believe he may have been fighting for the entertainment of others, but it is remarkable that the first osteo-archaeological evidence for this kind of gladiatorial combat has been found so far from the Colosseum of Rome, which would have been the classical world’s Wembley Stadium of combat.”

Provided by PLOS

Categories : VaccinesTags :

Funding Cuts Risk the Resurgence of Preventable Diseases, WHO Warns

On By ModernMedia
Photo by Mufid Majnun on Unsplash

The World Health Organization warns that global health funding cuts are paving the way for a resurgence of diseases that had been brought to the brink by vaccination.

One example of prior success is Africa’s “meningitis belt”, spanning parts of sub-Saharan Africa, where vaccination campaigns had successfully eliminated meningitis A. Likewise, yellow fever and related deaths were drastically cut by improved routine immunisation and emergency vaccine stockpiles.

The WHO says that this hard-won progress is now threatened. “Funding cuts to global health have put these hard-won gains in jeopardy,” warned Tedros Adhanom Ghebreyesus, WHO Director-General.

Outbreaks on the rise

In 2023, measles cases were estimated at more than 10.3 million – a 20% year-on-year increase. In a statement marking the beginning of World Immunization Week, the WHO, UN Children’s Fund UNICEF and their partners warned that this upward trend is expected to continue into 2025.

After years of declining cases in Africa thanks to improved vaccine access, yellow fever is also making a return. The start of 2025 has already seen a rise in outbreaks across the continent, with cases also confirmed in the Americas.

The threat of vaccine misinformation

Vaccination efforts are increasingly under pressure due to a combination of misinformation, population growth, humanitarian crises, and funding cuts.

Earlier this month, a WHO review across 108 countries found that nearly half are experiencing moderate to severe disruptions to vaccination campaigns, routine immunisations, and supply chains due to falling donor support.

“The global funding crisis is severely limiting our ability to vaccinate over 15 million vulnerable children in fragile and conflict-affected countries against measles,” said Catherine Russell, Executive Director of UNICEF.

High healthcare returns on vaccination

Vaccines save around 4.2 million lives each year, protecting against 14 different diseases. Almost half of those lives are saved in Africa.

Despite this, falling investment now risks the re-emergence of diseases once thought to be under control.

Health experts emphasise that immunisation is one of the most cost-effective health interventions. Every $1 invested in vaccines brings an estimated return of $54 through better health and economic productivity.

UNICEF, WHO, and their partners are calling on parents, the public, and political leaders to support immunisation programmes and ensure long-term investment in vaccines and public health systems.

Source: WHO

Categories : Cancer Cardiovascular DiseaseTags :

Statin Use May Improve Survival in Patients for Some Blood Cancers

On By ModernMedia
Photo by Towfiqu Barbhuiya on Unsplash

Patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk of dying from their cancer compared to similar patients who were not taking statins, according to a study published today in the journal Blood Advances.

“This is the first systematic evaluation of the association of statin use with survival outcomes in patients with CLL or SLL who have been treated with contemporary targeted agents such as ibrutinib,” said the study’s principal investigator, Ahmad Abuhelwa, PhD, an assistant professor of pharmacy practice and pharmacotherapeutics at the University of Sharjah in the United Arab Emirates. “Our results highlight a strong link between statin use and improved survival in this patient population.”

CLL is a slow-growing cancer that starts in the blood-forming cells of the bone marrow and is the most common form of leukaemia in adults in the United States. SLL, also a slow-growing cancer, affects the same type of cells as CLL but starts in lymphoid tissues such as the spleen instead of in the blood-forming cells.

Statins are among the most widely prescribed medications. It’s estimated that over 90 million adults in the United States take a statin drug to reduce their cholesterol levels and lower their risk for heart disease, which can lead to heart attacks or strokes. Previous studies have linked statin use to reduced death rates from several cancers, including CLL, said Dr Abuhelwa. However, those studies did not evaluate the effects of statin use in patients who were treated with newer cancer therapies such as the targeted drug ibrutinib, he said.

In the current study, Dr Abuhelwa and his colleagues analysed data from 1467 patients with CLL or SLL who participated in four international clinical trials conducted between 2012 and 2019. In these trials, patients were randomly assigned to treatment with ibrutinib either alone or in combination with other anti-cancer drugs, or to a drug regimen that did not include ibrutinib. A total of 424 patients (29%) were taking a statin at the time they started treatment across the four clinical trials. The median patient age was 65, and 66% were men; 92% had CLL, which was either newly diagnosed, had come back, or had not responded to prior treatment.

The study’s primary endpoints were cancer-specific survival (how long patients lived after starting treatment before dying specifically from their cancer), overall survival (how long patients lived after starting treatment, regardless of the cause of death), and progression-free survival (how long patients lived after starting treatment before their cancer worsened or they died from any cause). The secondary endpoint was the proportion of patients who experienced severe or life-threatening adverse events. The median follow-up time for all patients enrolled in the four trials was five years for overall survival and 22 months for progression-free survival.

To account for potential confounding factors, the investigators adjusted their analysis for variables including each patient’s diagnosis, age, sex, weight, physical functioning (as assessed by doctors), disease severity, length of time since their diagnosis, number of co-existing illnesses, use of other medications for heart conditions or high blood pressure, and the specific anti-cancer treatment regimen received.

Results showed that, regardless of any of these factors, patients who took a statin had, on average, a 61% reduced risk of dying from their cancer, a 38% reduced risk of death from any cause, and a 26% reduced risk of disease progression. Importantly, statin use did not increase the likelihood of severe or life-threatening adverse events.

“These findings don’t allow us to say for certain that statins directly improve cancer outcomes,” said Dr. Abuhelwa. “However, the fact that this association remained strong even after accounting for multiple factors makes it an important area for future research.” As next steps, he recommended conducting laboratory studies to better understand how statins may influence cancer biology, as well as prospective clinical trials in which patients with CLL or SLL are randomly assigned to take a statin or not.

The study has several limitations given its observational nature. For example, patients enrolled in clinical trials tend to be monitored more closely than those who receive treatment outside of a clinical trial, so the study findings may not be generalizable to patients treated in non-clinical trial settings. Additionally, because patients used various statins at different doses, the study could not determine the effects of specific statin types, doses, or duration of use on patients’ survival.

“While our results are very promising, we can’t recommend starting statins for CLL/SLL treatment based on this study alone,” Dr Abuhelwa said. “Future clinical trials are needed to determine definitively whether statins have a direct benefit on cancer survival.”

Source: American Society of Hematology

Categories : UncategorizedTags :

Adolescents Who Sleep Longer Perform Better at Cognitive Tasks

On By ModernMedia
Photo by Eren Li

Adolescents who sleep for longer – and from an earlier bedtime – than their peers tend to have improved brain function and perform better at cognitive tests, researchers from the UK and China have shown.

But the study of adolescents in the US also showed that even those with better sleeping habits were not reaching the amount of sleep recommended for their age group.

Sleep plays an important role in helping our bodies function. It is thought that while we are asleep, toxins that have built up in our brains are cleared out, and brain connections are consolidated and pruned, enhancing memory, learning, and problem-solving skills. Sleep has also been shown to boost our immune systems and improve our mental health.

During adolescence, our sleep patterns change. We tend to start going to bed later and sleeping less, which affects our body clocks. All of this coincides with a period of important development in our brain function and cognitive development. The American Academy of Sleep Medicine says that the ideal amount of sleep during this period is between eight- and 10-hours’ sleep.

Professor Barbara Sahakian from the Department of Psychiatry at the University of Cambridge said: “Regularly getting a good night’s sleep is important in helping us function properly, but while we know a lot about sleep in adulthood and later life, we know surprisingly little about sleep in adolescence, even though this is a crucial time in our development. How long do young people sleep for, for example, and what impact does this have on their brain function and cognitive performance?”

Studies looking at how much sleep adolescents get usually rely on self-reporting, which can be inaccurate. To get around this, a team led by researchers at Fudan University, Shanghai, and the University of Cambridge turned to data from the Adolescent Brain Cognitive Development (ABCD) Study, the largest long-term study of brain development and child health in the United States.

As part of the ABCD Study, more than 3200 adolescents aged 11-12 years old had been given FitBits, allowing the researchers to look at objective data on their sleep patterns and to compare it against brain scans and results from cognitive tests. The team double-checked their results against two additional groups of 13-14 years old, totalling around 1190 participants. The results are published today in Cell Reports.

The team found that the adolescents could be divided broadly into one of three groups:

Group One, accounting for around 39% of participants, slept an average (mean) of 7 hours 10 mins. They tended to go to bed and fall asleep the latest and wake up the earliest.

Group Two, accounting for 24% of participants, slept an average of 7 hours 21 mins. They had average levels across all sleep characteristics.

Group Three, accounting for 37% of participants, slept an average of 7 hours 25 mins. They tended to go to bed and fall asleep the earliest and had lower heart rates during sleep.

Although the researchers found no significant differences in school achievement between the groups, when it came to cognitive tests looking at aspects such as vocabulary, reading, problem solving and focus, Group Three performed better than Group Two, which in turn performed better than Group One.

Group Three also had the largest brain volume and best brain functions, with Group One the smallest volume and poorest brain functions.

Professor Sahakian said: “Even though the differences in the amount of sleep that each group got was relatively small, at just over a quarter-of-an-hour between the best and worst sleepers, we could still see differences in brain structure and activity and in how well they did at tasks. This drives home to us just how important it is to have a good night’s sleep at this important time in life.”

First author Dr Qing Ma from Fudan University said: “Although our study can’t answer conclusively whether young people have better brain function and perform better at tests because they sleep better, there are a number of studies that would support this idea. For example, research has shown the benefits of sleep on memory, especially on memory consolidation, which is important for learning.”

The researchers also assessed the participants’ heart rates, finding that Group Three had the lowest heart rates across the sleep states and Group One the highest. Lower heart rates are usually a sign of better health, whereas higher rates often accompany poor sleep quality like restless sleep, frequent awakenings and excessive daytime sleepiness.

Because the ABCD Study is a longitudinal study – that is, one that follows its participants over time – the team was able to show that the differences in sleep patterns, brain structure and function, and cognitive performance, tended be present two years before and two years after the snapshot that they looked at.

Senior author Dr Wei Cheng from Fudan University added: “Given the importance of sleep, we now need to look at why some children go to bed later and sleep less than others. Is it because of playing videogames or smartphones, for example, or is it just that their body clocks do not tell them it’s time to sleep until later?”

The research was supported by the National Key R&D Program of China, National Natural Science Foundation of China, National Postdoctoral Foundation of China and Shanghai Postdoctoral Excellence Program. The ABCD Study is supported by the National Institutes of Health.

Reference

Ma, Q et al. Neural correlates of device-based sleep characteristics in adolescents. Cell Reports; 22 Apr 2025; DOI: 10.1016/j.celrep.2025.115565


Republished under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Read the original article.

Categories : Antibiotics Infection ControlTags :

Using Blue Light to Fight Drug-resistant Infections

On By ModernMedia
Pseudomonas aeruginosa. Source: Wikimedia Commons

Researchers at the University of Oklahoma have made a breakthrough discovery that could potentially revolutionise treatments for antibiotic-resistant infections, cancer and other challenging gram-negative pathogens without relying on precious metals.

Currently, precious metals like platinum and rhodium are used to create synthetic carbohydrates, which are vital components of many approved antibiotics used to combat gram-negative pathogens, including Pseudomonas aeruginosa, a notorious hospital-acquired infection responsible for the deaths of immunocompromised patients. However, these elements require harsh reaction conditions, are expensive to use and are harmful to the environment when mined. In an innovative study published in the journal Nature Communications, an OU team led by Professor Indrajeet Sharma has replaced these precious metals with either blue light or iron, achieving similar results with significantly lower toxicity, reduced costs, and greater appeal for researchers and drug manufacturers.

By using abundant, inexpensive, iron or metal-free, non-toxic blue light, the team can more easily and rapidly synthesize these important carbohydrates. Since most antibiotics rely on a carbohydrate molecule to penetrate the thin, external layer of the gram-negative bacteria, this discovery could transform the way doctors treat multi-drug-resistant pathogens.

“Drug-resistant infections are a major problem and are expected to rise unless something is done,” Sharma said. “By using our methods to make late-stage drug modifications, synthetic carbohydrate-based antibiotics could help treat these infections. Furthermore, since carbohydrates can also increase a drug’s solubility, they can be easily deployed as a pro-drug that a patient can simply take it with water.”

A pro-drug is a medication that it less active when administered and metabolized into its active form. To help drug molecules last longer in the body and work more effectively, Sharma’s team is exploring ways to attach specially designed sugars or unnatural sugar to them. They are using a unique blue light-based method, developed by Surya Pratap Singh, a lead researcher and doctoral student in Dr. Sharma’s lab, that does not require metals.

“If a drug molecule is broken down too quickly, it loses its potency. By replacing an oxygen atom in the carbohydrate molecule with a sulfur one, enzymes in the human body won’t recognise the molecule as a carbohydrate and won’t break it down as quickly,” Sharma said. “These modified compounds, commonly called thiosugars, could be used to more effectively treat infections and diseases like cancer.”

Source: University of Oklahoma

Categories : New Compounds and Treatments Respiratory DiseasesTags :

Pulmonary Fibrosis has no Cure: Could a Cancer Drug Hold the Answer?

On By ModernMedia
Credit: Scientific Animations CC4.0

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

IPF is rapidly progressive and causes scarring in the lungs, making it difficult to breathe. Approximately 50% of patients die within three years of diagnosis, and current treatments can only slow the disease – not stop or reverse it. 

In a study published in the Journal of Clinical Investigation, Tulane scientists found that an FDA-approved cancer drug may help the immune system clear out the damaged cells that cause the lung scarring, potentially restoring lung function in patients with the disease.

In healthy lungs, specialised cells called fibroblasts help repair lung tissue. But in people with IPF, some fibroblasts and nearby epithelial cells stop functioning properly. These so-called “senescent” cells no longer divide or die as they should. Instead, they build up and contribute to stiff, scarred lungs.

Tulane researchers discovered that these senescent cells appear to accumulate when the immune system’s natural ability to remove them is blocked. The culprit: a protein called CTLA4, which acts as an emergency brake on immune system activity.

By using ipilimumab — an immunotherapy drug currently used to treat various cancers — the researchers were able to block CTLA4 in mice. This released the “brakes” on certain immune cells called T cells, reactivating their ability to clear out the senescent fibroblasts. As a result, the mice showed significantly improved lung tissue regeneration and reduced scarring.

“The CTLA4 protein normally functions to prevent excessive inflammation by blocking overactive T cells,” said senior author Dr. Victor Thannickal, professor and Harry B. Greenberg Chair of Medicine at Tulane University’s John W. Deming Department of Medicine. “Too much of this ‘blocker protein’ may result in losing the ‘good’ inflammation that is needed to remove senescent cells. What we’re doing is blocking the blocker.”

The researchers zeroed in on CTLA4 as a potential therapeutic target when they analyzed both human and mouse IPF lung tissue and found unusually high levels of CTLA4 on the T cells in the areas where scarring was most prevalent.

Mice that received ipilimumab showed significantly improved lung repair ability and recovered faster than mice that did not receive the drug. 

“This opens up an entirely new direction for potential treatment of IPF,” said lead author Santu Yadav, PhD, assistant professor of medicine at the Tulane University School of Medicine. “Instead of using drugs to kill senescent cells, we are re-activating our own immune system to clear them out.”

More research is needed to determine the efficacy of drugs that target CTLA4 or other so-called “checkpoint proteins” to rejuvenate the immune system. A primary concern is determining a safe dosing strategy that allows for the immune system to attack senescent cells without causing harmful levels of inflammation. 

IPF is a disease of aging and is rarely seen before age 50. These findings also offer hope that this approach could work for other similar aging related diseases. 

“If it works in IPF, this immune rejuvenating approach to treatment may be effective in other diseases such as Alzheimer’s or cardiovascular diseases in which senescent cells are known to accumulate,” Thannickal said. “Can the right drug activate T cells in a way that clears senescent cells without causing collateral damage? If so, we may be closer to combating many aging related diseases and perhaps even aging itself.” 

Source: Tulane University

Categories : Mental Health OphthalmologyTags :

Genetic Schizophrenic Susceptibility Could Show up in the Retina

On By ModernMedia
Photoreceptor cells in the retina. Credit: Scientific Animations

Could the eyes, which are directly connected to the brain, hold clues to brain changes? An international team of researchers led by the University of Zurich and the University Hospital of Psychiatry Zurich has now tackled this very question. In their study, published in Nature Mental Health, the researchers examined whether changes in our nerve connections are linked to a genetic risk for schizophrenia, as impaired neural information processing is one of the main characteristics of the disorder.

Previous studies suggest that schizophrenia not only reduces volume of grey matter in the brains of those affected, but that it also leads to loss of retinal tissue. But whether these changes are the cause of schizophrenia or a consequence of the disorder has remained unanswered. Retinal health could also be affected by schizophrenia itself, for example, through antipsychotic medication, lifestyle factors or diabetes.

Extensive use of data from healthy individuals

“To investigate whether the risk of developing schizophrenia has an effect on the central nervous system, we examined tens of thousands of healthy individuals,” says Finn Rabe, first author of the study and postdoc at the University of Zurich. “We then calculated polygenic risk scores for each individual.”

The researchers were able to use extensive genetic and retinal data taken from the UK Biobank, a large biomedical database containing data from over half a million people. “You could say that the scale of the UK Biobank’s data has revolutionised biomedical research,” the researcher adds.

Thin retina, elevated risk

The study shows that higher genetic susceptibility to schizophrenia is indeed associated with thinner retinas. The effects are small, though, and can only be reliably demonstrated in large-scale studies. One of the study’s findings is that, unlike changes in the brain, changes in the retina are easy to detect using non-invasive and inexpensive retinal measurements. Thanks to optical coherence tomography, which can be described as a kind of ultrasound for the eye, retinal thickness can be measured in minutes.

This offers a promising outlook for prevention. “Our study shows the potential of using optical coherence tomography in clinical practice. But large-scale longitudinal studies are needed to examine how useful it will be for prevention,” says Finn Rabe.

Perspectives for new therapies

Another key finding of the study concerns genetic variants associated with inflammatory processes in the brain. These may also contribute to structural changes in the retina. The study thus offers further support for the inflammation hypothesis of schizophrenia, ie, the idea that inflammatory processes contribute to the development or progression of the disorder. “If this hypothesis is confirmed, inflammation could be interrupted by medication, potentially enabling us to improve treatment possibilities in the future,” says Rabe.

Source: University of Zurich

Categories : Ethics and Law UrogenitalTags :

Court Rules that UTI Drug Trade Names are Too Similar

On By ModernMedia
Photo by Bill Oxford on Unsplash

A court case over the trade names of two urinary tract infection (UTI) drugs has been settled. The court ordered that Cipla Medpro be restrained from using the trade name Furizome as it is too similar to Adcock Ingram’s UTI drug Urizone, leading to potential confusion by consumers. In his ruling, Justice James Lekhuleni of the High Court, Western Cape Division, who stated that despite safeguards against confusion in prescribing, ultimately “doctors are human”, so miscommunications could occur – and that the agency of patients cannot be ignored.

The trademark infringement case was brought by three applicants: Adcock Ingram Limited, Adcock Ingram Healthcare (Pty) LTD, and Italian company Zambon S.P.A. Zambon is the owner of the name Urizone, which is used under licence. Urizone had been launched in South Africa in 1993. The applicants stated that more than 3 million sachets had been sold between 2011 and 2023, with R5 million in advertising spent to promote the drug between 2018 and 2022 alone.

The applicants brought the case that Cipla Medpro’s Furizome, with the active ingredient fosfomycin, was too similar to their own product, Urizone, which contained the same ingredient in 3g sachets, and thus could confuse consumers. They alleged that Cipla Medpro sought to capitalise on the reputation earned by Urizone.

The applicants made the case that, despite Urizone being made available as a generic, none of the pharmaceutical companies producing it chose to use the name. When Furizome was launched, Adcock Ingram sent a letter of demand to Cipla to stop using the name due to its . Cipla, through its attorneys, rebutted the claim, saying that the two are sufficiently distinct to avoid confusion, with the “F” alluding to the fosfomycin ingredient. Cipla contended that it had already submitted the name through SAHPRA, and

Cipla also contended that the consumer – the patient – would not be misled during the prescribing and purchase of a schedule 4 medication as they would be informed by the pharmacist of the two different drugs.

In considering the judgment, the court noted that a test as to whether trademarks are be similar can be mode on a phonetic basis, or if they conceptually or visually similar. A trademark’s essential function is to indicate the origin of the goods in connection with which it is used. The “N” and “M” where seen as visually and phonetically similar, and “furi” was similar phonetically to “uri“. This could cause confusion and miscommunication even between doctors as to what drug they had prescribed a patient.

While Justice Lekhuleni acknowledged the safeguards of prescribing schedule 4 medications, he pointed out that the general public had become much more knowledgeable about prescription drugs in the past two decades. On this, he wrote “…the reality is that patients are involved in the process of deciding which medicines they will use, and that creates the risk of confusion. This situation in turn creates a responsibility upon pharmaceutical companies to make sure that they adopt trade marks that are not confusingly similar.”

Categories : Lab Tests and ImagingTags :

Simpler Blood Glucose Monitoring to Delay or Prevent Onset of Diabetes

On By ModernMedia
Photo by Photomix Company on Pexels

The highs and lows of blood glucose aren’t just an energy rollercoaster; they could be a key to detecting diabetes risk early and spare a needle prick or two.

Researchers at the University of Tokyo have identified a simple, noninvasive method for assessing blood glucose regulation – an essential factor in diabetes risk. Their approach, based on continuous glucose monitoring (CGM) data, could improve early detection and risk assessment for diabetes without relying on blood samples and expensive or complex procedures.

The study is published in Communications Medicine.

Often called a “silent epidemic,” diabetes is an increasingly prevalent global health concern, with significant health and economic consequences. Early detection of impaired glucose regulation – an intermediate stage between normal blood glucose levels and diabetes – is essential for preventing or delaying the onset of Type 2 diabetes. Conventional diagnostic tools, however, often miss early signs because they rely on periodic blood samples rather than continuous monitoring.

“Traditional diabetes tests, while useful, do not capture the dynamic nature of glucose regulation under physiological conditions,” said Shinya Kuroda, a professor at the University of Tokyo’s Graduate School of Science and co-author of the current study.

To find a more practical alternative, the team turned to CGM, a wearable technology that continuously tracks glucose levels in real time, providing a clearer picture of blood glucose fluctuations in everyday life. Their goal was to identify a CGM-based method for estimating glucose handling capacity, which maintains stable levels, without invasive procedures.

The team analyzed 64 individuals without a prior diabetes diagnosis, using a CGM device, oral glucose tolerance tests (OGTT), and clamp tests that are used to assess insulin sensitivity and glucose metabolism. They then validated their findings with an independent dataset and mathematical simulations.

Their analysis showed that AC_Var, a measure of glucose-level fluctuations, strongly correlates with the disposition index, a well-established predictor of future diabetes risk. Moreover, the researchers’ model, which combines AC_Var with glucose standard deviation, outperformed traditional diabetes markers – such as fasting blood glucose, HbA1c and OGTT results – in predicting the disposition index.

“By analysing CGM data with our new algorithm, we identified individuals with impaired glycaemic control – even when standard diagnostic tests classified them as ‘normal,’” said Kuroda. “This means we can potentially detect issues much earlier, creating an opportunity for preventive interventions before diabetes is diagnosed.”

The team also showed that the method was more accurate than conventional diagnostic indicators in predicting diabetes complications such as coronary artery disease. To facilitate broader access to this approach, the research team has developed a web application that allows individuals and health care providers to easily calculate these CGM-based indices.

“Our ultimate goal is to provide a practical, accessible tool for widespread diabetes screening,” Kuroda said. “By enabling early detection of glucose regulation abnormalities, we hope to prevent or delay disease onset and reduce long-term complications.”

Source: University of Tokyo